New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.
Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The Sabin Product Development Partnership, and the Global Network for Neglected Tropical Diseases.

Reposted with permission from the TAMEST blog, which is run by the Academy of Medicine, Engineering & Science of Texas. 

Field research, such as that conducted for clinical trials or disease surveillance, is essential to address the many pervasive health issues in developing countries. It relies on extensive collaboration between research institutions and groups on the ground.

To highlight the extensive body of knowledge collected in developing the Global Vaccine Action Plan (GVAP), the journal Vaccine today released a special supplement dedicated in full to the Decade of Vaccines.